WithdrawnPhase 2NCT04480450

Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy

Studying Chronic inflammatory demyelinating polyneuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Kansas Medical Center
Principal Investigator
Mazen Dimachkie, MD
University of Kansas Medical Center
Intervention
Rituximab(drug)
Eligibility
18 years · All sexes
Timeline
20252025

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04480450 on ClinicalTrials.gov

Other trials for Chronic inflammatory demyelinating polyneuropathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic inflammatory demyelinating polyneuropathy

← Back to all trials